Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab
Sven G. Meuth(University of Würzburg), Steffen Pfeuffer(Justus-Liebig-Universität Gießen), Hagen B. Huttner(Justus-Liebig-Universität Gießen), Bruce Cree(University of California, San Francisco), Konstanze Kleinschnitz(University of Duisburg-Essen), Matthias Grothe(Universitätsmedizin Greifswald), S. Wolff(Justus-Liebig-Universität Gießen), Refik Pul, Tobias Bopp(Johannes Gutenberg University Mainz), Saskia Räuber(University of Münster), Tobias Ruck(University Hospital Münster), Kathrin Möllenhoff(University of Cologne), Hans‐Peter Hartung(The University of Sydney), Alice Willison(Düsseldorf University Hospital), Franz Felix Konen(Medizinische Hochschule Hannover), Anna Mück(Justus-Liebig-Universität Gießen), Thomas Skripuletz(Medizinische Hochschule Hannover), Marc Pawlitzki(Düsseldorf University Hospital), Christoph Kleinschnitz
Cited by 19
Related Papers
Animal models of ischemic stroke and their application in clinical research
|Drug Design Development and Therapy|2015|639
Interferon-Regulatory Factor 4 Is Essential for the Developmental Program of T Helper 9 Cells
|Immunity|2010|539
Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis
|The Journal of Experimental Medicine|2006|447
Mapping Multiple Sclerosis Susceptibility to the HLA-DR Locus in African Americans
|The American Journal of Human Genetics|2004|345